345 Park Avenue South

Mega Menu WP The Core Labs Behind the Deals - Image

Blue

News & Insights

Your Home in NYC

Cure Founders Pass Membership Benefits 03 Tab Bar Image

Dark Blue

Apply for Membership

Where Healthcare Innovators Connect

Magenta

Events

Accelerating Advances in Health

Green

About

Contact Us

Michael Foley, PhD, is the Chief Executive Officer, Deerfield Discovery and Development. Foley joined Deerfield in 2018 to focus on research collaborations. Most recently, he was the CEO and Sanders Director at Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) where he led the efforts to discover drug candidates in an academic setting.

Prior to Tri-I TDI, he was Director of the Chemical Biology Platform at the Broad Institute of MIT and Harvard. Foley is the founder of Forma Therapeutics. In 2001, he founded Infinity Pharmaceuticals and in 2000, he founded CombinatoRx. He was a GlaxoSmithKline Fellow at Harvard University and previously a Research Chemist at GlaxoSmithKline. 

Foley began his career at Bristol Myers Squibb as a Research Chemist. He received his BS from St. Norbert College, his MS from Utah State University and his PhD from Harvard University.

Chief Executive Officer, Deerfield Discovery and Development

Join Seema Kumar, CEO of Cure and Michael Foley, CEO of Deerfield Discovery & Development, for an evening of groundbreaking keynotes by two leading scientists: Bartosz Grzybowski, PhD, and Marty Burke, PhD. These two luminaries are applying AI, advanced synthetic chemistry, and decades of accumulated knowledge of functional molecules to advance the field of small molecule chemistry. They will discuss applications of their work in case studies that demonstrate the power of innovation in the fields of drug discovery, global chemical production, and national (bio)chemical security.

Welcome to the Molecular Industrial Revolution